Smith & Nephew plc (LON:SN) insider Virginia Bottomley acquired 223 shares of the stock in a transaction dated Wednesday, August 16th. The stock was acquired at an average cost of GBX 1,380 ($17.92) per share, for a total transaction of £3,077.40 ($3,995.07).

Smith & Nephew plc (LON:SN) traded up 0.66% on Wednesday, hitting GBX 1377.00. 1,768,759 shares of the stock traded hands. Smith & Nephew plc has a 12-month low of GBX 1,064.91 and a 12-month high of GBX 1,390.00. The company’s 50 day moving average price is GBX 1,326.16 and its 200-day moving average price is GBX 1,282.93. The stock’s market capitalization is GBX 12.06 billion.

The firm also recently declared a dividend, which will be paid on Wednesday, November 1st. Stockholders of record on Thursday, October 5th will be paid a dividend of $0.12 per share. The ex-dividend date of this dividend is Thursday, October 5th. This represents a dividend yield of 0.72%.

COPYRIGHT VIOLATION WARNING: “Insider Buying: Smith & Nephew plc (SN) Insider Purchases 223 Shares of Stock” was originally reported by Watch List News and is the sole property of of Watch List News. If you are reading this article on another site, it was copied illegally and republished in violation of international trademark & copyright law. The original version of this article can be accessed at https://www.watchlistnews.com/insider-buying-smith-nephew-plc-sn-insider-purchases-223-shares-of-stock/1495610.html.

Several equities analysts have recently issued reports on SN shares. Shore Capital reaffirmed a “hold” rating and issued a GBX 1,144 ($14.85) price objective on shares of Smith & Nephew plc in a research note on Friday, May 5th. J P Morgan Chase & Co lowered their price objective on shares of Smith & Nephew plc from GBX 1,345 ($17.46) to GBX 1,280 ($16.62) and set a “neutral” rating on the stock in a research note on Monday, May 15th. HSBC Holdings plc reaffirmed a “hold” rating and issued a GBX 1,320 ($17.14) price objective on shares of Smith & Nephew plc in a research note on Wednesday, April 26th. Credit Suisse Group lifted their price objective on shares of Smith & Nephew plc from GBX 1,160 ($15.06) to GBX 1,200 ($15.58) and gave the stock a “neutral” rating in a research note on Monday, May 8th. Finally, Morgan Stanley reaffirmed an “overweight” rating on shares of Smith & Nephew plc in a research note on Monday, May 15th. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and two have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of GBX 1,289.25 ($16.74).

Smith & Nephew plc Company Profile

Smith & Nephew plc is a medical technology company. The Company is engaged in developing, manufacturing, marketing and selling medical devices and services. Its products and services include Sports Medicine Joint Repair, Arthroscopic Enabling Technologies (AET), Trauma & Extremities, Other Surgical Businesses, Knee Implants, Hip Implants, Advanced Wound Care, Advanced Wound Bioactives and Advanced Wound Devices.

Receive News & Ratings for Smith & Nephew plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew plc and related companies with Analyst Ratings Network's FREE daily email newsletter.